Lytix Biopharma AS (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 7.34
+0.08 (1.10%)
Sep 17, 2025, 9:43 AM CET
Lytix Biopharma AS Revenue
Lytix Biopharma AS had revenue of 608.00K NOK in the twelve months ending June 30, 2025, down -95.79% year-over-year. In the year 2024, Lytix Biopharma AS had annual revenue of 11.13M with 178.98% growth.
Revenue (ttm)
608.00K
Revenue Growth
-95.79%
P/S Ratio
815.10
Revenue / Employee
76.00K
Employees
8
Market Cap
495.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.13M | 7.14M | 178.98% |
| Dec 31, 2023 | 3.99M | -7.04M | -63.82% |
| Dec 31, 2022 | 11.03M | -8.28M | -42.87% |
| Dec 31, 2021 | 19.31M | 15.23M | 373.91% |
| Dec 31, 2020 | 4.07M | -2.27M | -35.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 628.08M |
| Nordhealth AS | 578.17M |
| Photocure ASA | 522.86M |
| ArcticZymes Technologies ASA | 104.33M |
| Vistin Pharma ASA | 452.25M |
| Omda AS | 458.96M |
| Gentian Diagnostics ASA | 163.38M |
| Nykode Therapeutics AS | 79.85M |